Ridvan Dumlu
Overview
Explore the profile of Ridvan Dumlu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ceylan B, Olmuscelik O, Karaalioglu B, Ceylan S, Sahin M, Aydin S, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685844
Studies attempting to predict the development of severe respiratory failure in patients with a COVID-19 infection using machine learning algorithms have yielded different results due to differences in variable selection....
2.
Mert A, Derin O, Akalin H, Dumlu R, Gundes S, Zengin R, et al.
Sci Rep
. 2024 Nov;
14(1):26337.
PMID: 39487308
Data in the literature on the use of ceftazidime-avibactam (CAZ-AVI) in carbapenem-resistant Klebsiella pneumoniae bloodstream infections (CRKP-BSIs) are limited especially in OXA-48 (Oxacillinase-48) predominant regions. Our study aimed to evaluate...
3.
Dumlu R, Sahin M, Derin O, Gul O, Basgonul S, Zengin R, et al.
Antibiotics (Basel)
. 2024 Oct;
13(10).
PMID: 39452256
: Ceftazidime-avibactam (CAZ-AVI) is recommended as first-line treatment for Oxacillinase-48 (OXA-48) β-Lactamase-producing carbapenem-resistant Enterobacterales (CRE) infections, while polymyxin-based combination therapies (PBCTs) are used as a last resort when CAZ-AVI is...
4.
Sahin M, Yilmaz M, Mert A, Naghili B, Ravanbakhsh F, Varshochi M, et al.
Med Mycol
. 2024 Jun;
62(7).
PMID: 38914466
The emergence of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), triggered a global pandemic. Concurrently, reports of mucormycosis cases surged, particularly during the second wave in India....
5.
Derin O, Sahin M, Dumlu R, Basgonul S, Bayrak A, Arduc S, et al.
Antibiotics (Basel)
. 2024 Jan;
13(1).
PMID: 38247649
Background: Managing bloodstream infections (BSIs) is challenging due to increasing antimicrobial resistance, limited therapeutic options, and high mortality rates. In this study, we aimed to identify 30-day mortality risk factors...
6.
Kilboz B, Ervatan Z, Dumlu R, Akan O
Eur J Neurol
. 2023 Jul;
30(10):3394-3396.
PMID: 37505930
Background And Purpose: The recent off-label use of botulinum neurotoxin (BoNT) for intragastric obesity treatment has led to 67 cases of systemic botulism in Türkiye, Germany, Austria and Switzerland. This...
7.
Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
Dumlu R, Yurttutan Uyar N, Ayas M, Aksoy N, Ozturk N, Kocagoz A
Turk J Med Sci
. 2023 Mar;
52(6):1839-1844.
PMID: 36945980
Background: Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its resistance by analyzing gram-negative bacteria isolated from various patient samples. Methods: Between March and...
8.
Senol E, Cilli A, Gunen H, Sener A, Dumlu R, Odemis A, et al.
Turk Thorac J
. 2022 Feb;
22(4):339-345.
PMID: 35110252
Objective: To evaluate the rate of pneumococcal pneumonia (PP) among patients with community-acquired pneumonia (CAP) in Turkey and to investigate and compare features of PP and non-PP CAP patients. Material...